Akebia Announces Establishment of Rare Kidney Disease Pipeline GlobeNewswire December 01, 2025 Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat, an sGC stimulator, initiated in focal segmental glomerulosclerosis (FSGS) Both […]

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire December 01, 2025 SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage

NioBay Metals Announces Brokered Life Offering and Concurrent Private Placement for Gross Proceeds of Up to C$5 Million GlobeNewswire December 01, 2025 NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTRÉAL, Dec. 01, 2025 (GLOBE NEWSWIRE) — NioBay Metals Inc. (TSX-V: NBY) (“NioBay” or the “Corporation“), is

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) GlobeNewswire December 01, 2025 TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of

Brunswick Exploration Reports More High-Grade Cesium and Lithium Values at Anatacau Main GlobeNewswire December 01, 2025 MONTREAL, Dec. 01, 2025 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company“) is pleased to announce more results from its inaugural drilling campaign at the Anatacau Main Project, located in the Eeyou Istchee-James

Q2 Metals Reports Multiple Wide, Mineralized Intercepts from Infill Drilling at the Cisco Lithium Project, Including 95.1 m and 81.9 m each Grading 1.56% Liâ‚‚O GlobeNewswire December 01, 2025 Highlights: Four (4) drill holes from the 2025 infill drill program with strong analytical results are reported herein: CS25-040: 12 separate intervals, including 95.1 metres (“m”)

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) GlobeNewswire December 01, 2025 TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of

Emerita Announces Airborne Mag-EM Geophysical Survey Over Western Spanish Pyrite Belt GlobeNewswire December 01, 2025 TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) — Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) announces a 1,536km Helicopter time-domain electromagnetic and magnetic (HTEM) aerial geophysical survey over the Iberian Belt West (IBW) project and

AtlasClear Delivers Breakout October Performance with Triple-Digit Revenue and Earnings Growth in Wilson-Davis FOCUS Filing October Revenue Up 128% Year-Over-Year; Net Income Up 169% as Wilson-Davis Continues Strong FY2026 Momentum GlobeNewswire December 01, 2025 TAMPA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a technology-enabled financial

Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 GlobeNewswire December 01, 2025 Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW